Significance of Pulmonary Arterial Pressure as a Prognostic Indicator in Lung-Dominant Connective Tissue Disease

Atsushi Suzuki¹, Hiroyuki Taniguchi¹*, Naohiro Watanabe², Yasuhiro Kondoh¹, Tomoki Kimura¹, Kensuke Kataoka¹, Toshiaki Matsuda¹, Toshiki Yokoyama¹, Koji Sakamoto², Osamu Nishiyama³, Yoshinori Hasegawa²

¹ Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan, ² Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, ³ Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine, Osaka-sayama, Osaka, Japan

Abstract

Background: Lung-dominant connective tissue disease (LD-CTD) is a new concept for classifying the subset of patients with interstitial pneumonia who have clinical features suggesting an associated CTD, but whose features fall short of a clear diagnosis of CTD under the current rheumatologic classification systems. The impact of mean pulmonary arterial pressure (MPAP) in LD-CTD has not been sufficiently elucidated.

Objectives: To evaluate the survival impact of MPAP measured during the initial evaluation in patients with LD-CTD.

Methods: We retrospectively analyzed the initial evaluation data of 100 LD-CTD patients undergoing pulmonary function test, 6-min walk test (6MWT), and right heart catheterization (RHC).

Results: The mean MPAP was 16.2±4.4 mm Hg, and 18 patients had MPAP≥20 mm Hg. A univariate Cox proportional hazard model showed that MPAP and several variables have a statistically significant impact on survival. With stepwise, multivariate Cox proportional analysis, MPAP (HR = 1.293; 95% CI 1.130–1.480; p = 0.001) and mean forced vital capacity (%FVC) % predicted (HR = 0.958; 95% CI 0.930–0.986; p = 0.004) were shown to be independent determinants of survival.

Conclusions: Higher MPAP and lower %FVC at the initial evaluation were significant independent prognostic factors of LD-CTD. MPAP evaluation provides additional information of disease status and will help physicians to predict mortality in LD-CTD.

Citation: Suzuki A, Taniguchi H, Watanabe N, Kondoh Y, Kimura T, et al. (2014) Significance of Pulmonary Arterial Pressure as a Prognostic Indicator in Lung-Dominant Connective Tissue Disease. PLoS ONE 9(9): e108339. doi:10.1371/journal.pone.0108339

Editor: Masataka Kuwana, Keio University School of Medicine, Japan

Copyright: © 2014 Suzuki et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: This work was supported in part by a grant-in-aid for the respiratory failure research group from the Japanese Ministry of Health, Labor and Welfare and NPO Respiratory Disease Conference. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: taniguchi@tosei.or.jp

Introduction

Pulmonary hypertension (PH) has many causes and is a source of significant mortality in affected individuals. Development of PH in the context of interstitial lung disease (ILD) is a well-recognized complication [1–5]. Meanwhile, some studies suggest that connective tissue disease (CTD)-associated PH is a prognostic factor, seen especially in systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) [6–9]. In addition, there is accumulating evidence that borderline PH (MPAP >20 mmHg) may be clinically relevant in both ILD and CTD [2,10].

Recently, Fischer et al. [11] proposed “lung-dominant CTD” (LD-CTD) as a new concept for classifying the subset of patients with interstitial pneumonia who have clinical features suggesting an associated CTD, but whose features fall short of a clear diagnosis of CTD under the current rheumatologic classification systems. Little information is available regarding prognostic factors in LD-CTD [12]. Considering the importance of PH in ILD and CTD, we assumed that PH might occur in the clinical course of LD-CTD patients and contribute to poor prognosis. The aim of this study was to evaluate whether MPAP predicts survival in LD-CTD patients in whom background, pulmonary function test, 6-min walk test (6MWT), and right heart catheterization (RHC) could be evaluated at the initial evaluation.
Methods

Study subjects

Six hundred nine patients with ILD were identified from among patients who underwent systematic evaluations between May 2007 and August 2012 at Tosei General Hospital. Systematic evaluations included pulmonary function test, 6MWT, and RHC. LD-CTD was diagnosed based on the criteria proposed by Fischer et al. when specific autoantibodies were present in the absence of extrathoracic features of a definite CTD [11]. Serological tests, including those for antinuclear antibody (ANA), rheumatoid factor (RF), anti-citrullinated peptide (CCP), anti-Scl 70 (Scl-70), anti-RO/SSA, anti-La/SSB, anti-double-stranded DNA (dsDNA), anti-Smith, anti-ribonucleoprotein (RNP), anti-RNA synthetase (Jo-1), and anti-centromere antibodies, were performed routinely when ILD was first suspected. Anti-PM-Scl antibodies were unmeasured. Patients were considered to have LD-CTD if they had one of the specific autoantibodies within one year of initial evaluation (Table 1). CTD was diagnosed when patients fulfilled the established criteria for rheumatoid arthritis, systemic lupus erythematosus (SLE), SSc, polymyositis/dermatomyositis, Sjögren’s syndrome (SjS), or MCTD [13–18]. Clinically amyopathic dermatomyositis (CADM) was diagnosed when a patient had a skin rash characteristic of DM without clinical evidence of muscle disease and with little or no increase in the serum creatine kinase (CK) level [16,19]. We excluded any patient with a pre-existing diagnosis of CTD. The following cases were also excluded: (1) patients had been treated with corticosteroids, immunosuppressive agents, PH targeted therapy and oxygen therapy before initial evaluation, (2) RHC was not performed within one month of initial evaluation, or pulmonary artery wedge pressure (PAWP) on RHC was over 15 mm Hg. Finally, 100 patients with LD-CTD were taken as subjects (Figure 1).

In this study, PH is defined by MPAP ≥ 20 mm Hg (including borderline PH). A previous study indicated that MPAP > 20 mm Hg is optimal for predicting the prognosis in IPF patients [2].

This study was approved by the Tosei General Hospital Institutional Review Board (IRB No.398). Patient approval and/or informed consent were waived because the study involved a retrospective review of patient records. Our institutional review board determined that ethical approval was not necessary and did not require the patient’s approval or informed consent.

Measurements

We studied patients’ characteristics, pulmonary function tests, PaO2, 6MWT, and hemodynamics. All patients underwent spirometry (CHESTAC-55V; Chest, Tokyo, Japan), according to the method described in the American Thoracic Society (ATS) 1994 update [20]. Single-breath diffusing capacity of the lung for carbon monoxide (DLCO) was also measured (CHESTAC-55V). The values for forced vital capacity (FVC) and DLCO were related to % predicted values [21]. 6MWT was conducted according to the ATS statement [22]. Briefly, all patients were tested under standardized conditions by trained technicians. Patients were instructed to walk as far as possible in 6 min, and the distance that patients could walk was recorded [23]. Oxygen saturation was also measured by pulse oximetry at rest for 5 min prior to and immediately after the test. Dyspnea was assessed with the modified Medical Research Council score (MMRC) scale, which includes 5 grades (0–4) of various physiological activities that provoke dyspnea [24]. After the patients had read the descriptive phrases, they selected the number that best corresponded to their level of dyspnea in daily living. Patients underwent Doppler echocardiography. Estimated right ventricular systolic pressure (ERVSP) was measured by the peak tricuspid regurgitant flow velocity using the modified Bernoulli equation [25–26]. RHC was performed using a Swan-Ganz catheter percutaneously via either the cubital vein or the femoral vein. At the time of catheterization, the pressure transducers were adjusted to reflect the midthorax in each patient before beginning the procedure. Cardiac output was measured with a thermodilution method. PAWP was measured at the end-expiratory phase.
Statistical analysis

Survival status was analyzed in February 2014. Continuous variables were expressed as means ± SD. Categorical variables were summarized by frequency. The MMRC score was analyzed as a continuous variable. Distribution of continuous variables was evaluated using the Shapiro-Wilk test. If both variables had a normal distribution, correlations were calculated using Pearson’s correlation test. If either variable had a nonnormal distribution, correlations were calculated using Spearman’s correlation test. When two continuous variables were compared, the t test was used for normal distributions and the Mann-Whitney test was used for nonnormal distributions. Univariate Cox’s proportional hazard models were used to examine the association of selected variables with survival. Variables that were significant (p < 0.05) in the univariate analysis were included in the multivariate model. To avoid multicollinearity, only one of the highly correlated variables (coefficient of correlation ≥0.9) was entered in the multivariate model, if present. A stepwise multivariate Cox’s proportional hazards model was then used for variables that were revealed to be significant with the univariate model, in order to select more significant variables. Using the methods of Kaplan-Meier and the log-rank test, we studied the impact on survival of variables. All tests were performed at a significance level of p < 0.05. Analysis was completed using IBM SPSS statistics version 19.

Results

The baseline characteristics of 100 patients are summarized in Table 2, and the autoantibody profile of the study cohort is shown in Table 3. ANA was the most frequently positive autoantibody. Seventy-two patients were positive for one antibody, 23 were positive for two antibodies, and 5 had three positive serological tests. Fifty patients underwent surgical lung biopsy. RHC data are summarized in Table 2. MPAP, cardiac index, PAWP, and pulmonary vascular resistance (PVR) were 16.2 ± 4.4 mm Hg, 3.10 ± 0.72 l/min/m², 7.1 ± 3.4 mm Hg, and 1.79 ± 0.96 Wood units, respectively. A histogram of MPAP is shown in Figure 2. Four patients had MPAP > 25 mm Hg, and 18 patients had MPAP ≥ 20 mm Hg. In addition, there was a significant but weak correlation between ERVSP by Doppler echocardiography and systolic PAP (r = 0.243; p = 0.021).

In the follow-up period, six patients showed a definite CTD. Rheumatoid arthritis was diagnosed in two cases, SSc in two, polymyositis in one, and SjS in one using the established criteria [13,15–17]. Fifty-four patients received pharmacologic therapy during the follow-up period. Thirty-nine patients were treated with corticosteroid and immunosuppressive agent, thirty-seven patients were treated with pirfenidone, and five patients were treated with PH

Table 1. Diagnostic criteria for lung-dominant connective tissue disease.

| Criteria derived from Reference 11. |
|-------------------------------------|
| ANA: antinuclear antibody; RF: rheumatoid factor; CCP: cyclic citrullinated peptide; Scl-70: Sclero 70; ds DNA: double-stranded DNA; RNP: ribonucleoprotein. |
| doi:10.1371/journal.pone.0108339.t001 |

Figure 2. Histogram of MPAP. doi:10.1371/journal.pone.0108339.g002
targeted therapy (sildenafil). Twenty-one patients received long-term oxygen therapy (LTOT). The mean observation period was 2.74±1.63 years. Twenty-four patients died during the observation period, 11 due to advanced respiratory failure, 9 due to acute exacerbation, 1 due to lung cancer, and 3 due to unknown causes. There were no deaths associated with PH. The univariate Cox regression model (Table 4) demonstrated that %FVC, %DLCO, PaO$_2$, MMRC, 6-min walk distance (6MWD), lowest SpO$_2$, MPAP, and PVR had statistically significant impacts on survival. The stepwise multivariate Cox regression model (Table 5) demonstrated that MPAP (HR = 1.293; 95% CI 1.130–1.480; p = 0.001) and %FVC (HR = 0.958; 95% CI 0.930–0.986; p = 0.004) had statistically significant impacts on survival. There was no correlation between MPAP and %FVC (r = −0.09; p = 0.447). In addition, there was no association between any autoantibody and clinical outcomes (data not shown).

Table 6 shows the baseline characteristics and physiology of patients using a cutoff point of 20 mm Hg of MPAP. %DLCO, PaO$_2$, 6MWD, and lowest SpO$_2$ were significantly lower in those with MPAP ≥20 mm Hg. MMRC, PAWP, and PVR were significantly higher in those with MPAP ≥20 mm Hg. Figure 3 shows a Kaplan-Meier curve that reveals significantly worse survival among patients whose MPAP was ≥20 mm Hg than among those whose MPAP was <20 mm Hg (log-rank test p = 0.005). The 5-year survival rates from the initial diagnosis were 50.0 and 82.0%, respectively.

Table 3. Autoantibody profile of the study cohort.

| Serological tests | N = 100 |
|-------------------|---------|
| High-titer ANA (>1:320) or RF (>60 IU/ml) | 57/100 |
| Nucleolar-ANA | 26/100 |
| Anti-CCP | 14/88 |
| Anti-Scl-70 | 2/99 |
| Anti-Ro/SS-A | 13/100 |
| Anti-La/SS-B | 1/93 |
| Anti-ds DNA | 5/99 |
| Anti-Smith | 0/88 |
| Anti-RNP | 1/88 |
| Anti-tRNA synthetase (Jo-1) | 2/99 |
| Anti-centromere | 6/78 |

Data are presented as number. Some patients had multiple positive serological tests. doi:10.1371/journal.pone.0108339.t003
Discussion

This is the first study, to our knowledge, to report the impact of MPAP on survival in LD-CTD patients. This study included patients with milder pulmonary function impairment (mean FVC 81.1%, mean DLCO 56.4%) and milder MPAP (mean MPAP 16.2 mm Hg) than subjects of previous studies, however, a higher MPAP was an independent prognostic predictor [2,12,27]. This result shows the importance of evaluating MPAP at an early time in patients with LD-CTD.

Using the methods of Kaplan-Meier and the log-rank test, patients with MPAP $\geq 20$ mm Hg had a significantly lower survival rate than those with MPAP $<$ 20 mm Hg in LD-CTD. Kimura et al. previously demonstrated the importance of PH in IPF patients at their initial workup using a cutoff point (MPAP $\geq 20$ mm Hg) in RHC [2]. Our studies also demonstrated that borderline PH was found to be closely associated with prognosis in LD-CTD, the same as in IPF. The strength of our study was that RHC was performed on all patients within one month of initial evaluation.

The pathogenesis of PH is likely complex and driven by multiple mechanisms [28–29]. As shown in Table 6, patients with PH (MPAP $\geq 20$ mm Hg) were found to have a lower PaO$_2$ and lowest SpO$_2$ during the 6MWT. Previous studies showed that hypoxia induces vasoconstriction and vascular remodeling through various factors, such as vascular endothelial growth factor and hypoxia-inducible factor 1 alpha [30]. Our results indicate that hypoxia may play a crucial role in the development of PH in LD-CTD. Previous studies also suggest a role for autoimmunity in the development of the pulmonary vascular changes in patients with CTD [28]. Therefore, immune and inflammatory mechanisms may also play a significant role in the pathogenesis of PH in patients with LD-CTD. Further investigation will be required to determine whether this is the case.

Another important point of this study is that LD-CTD has several prognostic factors. The univariate Cox regression model demonstrated that %FVC, %DLCO, PaO$_2$, MMRC, 6MWD, lowest SpO$_2$, MPAP, and PVR had statistically significant impacts on survival. With stepwise, multivariate Cox proportional analysis, MPAP and %FVC were shown to be independent determinants of survival. Alhamad et al. [12] showed that a lower resting SpO$_2$ level and lower serum albumin were associated with an increased risk of death in LD-CTD, using a univariate Cox model. However, their study did not identify independent predictors of mortality due to the small sample size and low number of deaths. Therefore, this

Table 4. Results of the univariate Cox proportional hazard model.

| Variables            | HR   | 95%CI         | P value |
|----------------------|------|---------------|---------|
| Sex                  |      |               |         |
| Male                 | 1    |               |         |
| Female               | 0.615| 0.253–1.500   | 0.285   |
| Age, years           | 1.051| 0.991–1.115   | 0.095   |
| BMI                  | 0.953| 0.856–1.061   | 0.375   |
| Smoking status       |      |               |         |
| Never                | 1    |               |         |
| Ever                 | 0.957| 0.423–2.162   | 0.915   |
| FVC, %predicted      | 0.954| 0.934–0.974   | <0.001  |
| DLCO, %predicted     | 0.940| 0.910–0.971   | <0.001  |
| PaO$_2$, mmHg        | 0.946| 0.909–0.985   | 0.007   |
| MMRC                 | 2.312| 1.500–3.563   | <0.001  |
| 6MWD, m              | 0.994| 0.991–0.998   | 0.001   |
| Lowest SpO$_2$, %    | 0.935| 0.896–0.935   | 0.002   |
| MPAP, mmHg           | 1.158| 1.063–1.261   | 0.001   |
| Cardiac index, lmin$^{-1}$m$^{-2}$ | 1.027| 0.583–1.808   | 0.927   |
| PAWP, mmHg           | 1.010| 0.892–1.143   | 0.873   |
| PVR, Wood units      | 2.012| 1.458–2.777   | <0.001  |

HR: hazard ratio; CI: confidence interval.
doi:10.1371/journal.pone.0108339.t004

Table 5. Results of stepwise multivariate Cox proportional hazard model.

| Variables          | HR   | 95%CI         | P value |
|--------------------|------|---------------|---------|
| MPAP, mmHg         | 1.293| 1.130–1.480   | <0.001  |
| FVC, %predicted    | 0.958| 0.930–0.986   | 0.004   |

Used for variables that were significant in univariate analysis (Table 4).
FVC, DLCO, PaO$_2$, 6MWD, Lowest SpO$_2$, MPAP.
doi:10.1371/journal.pone.0108339.t005
study is the first to identify independent prognostic factors in LD-CTD.

CTD-ILD patients tend to be treated with immunosuppressive therapies, although there have been few systematic and prospec-

### Table 6. Baseline characteristics and physiology of patients with and without PH.

| Variables                  | Non PH MPAP<20 mmHg (N = 82) | PH MPAP≥20 mmHg (N = 18) | P value |
|----------------------------|-------------------------------|---------------------------|---------|
| Sex (M/F)                  | 51/31                         | 13/5                      | 0.425   |
| Age, years                 | 64.5 ± 8.3                    | 67.9 ± 6.4                | 0.104   |
| BMI                        | 23.5 ± 3.8                    | 24.8 ± 4.6                | 0.195   |
| Smoking status             |                               |                           |         |
| Ever/never                 | 48/34                         | 13/5                      | 0.283   |
| FVC, %predicted            | 82.9 ± 19.9                   | 73.2 ± 20.9               | 0.066   |
| DLCO, %predicted           | 58.4 ± 19.6                   | 46.8 ± 13.7               | 0.031   |
| PaO2, mmHg                 | 82.0 ± 11.6                   | 75.2 ± 10.6               | 0.026   |
| MMRC                       | 0.9 ± 0.8                     | 1.7 ± 1.4                 | 0.030   |
| 6MWD, m                    | 586.3 ± 121.1                 | 433.4 ± 164.3             | 0.001   |
| Lowest SpO2, %             | 85.2 ± 8.8                    | 81.5 ± 7.7                | 0.044   |
| MPAP, mmHg                 | 14.7 ± 3.0                    | 23.0 ± 3.3                | <0.001  |
| Cardiac index, l·min⁻¹·m⁻² | 3.07 ± 0.74                   | 3.20 ± 0.67               | 0.351   |
| PAWP, mmHg                 | 6.6 ± 3.2                     | 9.7 ± 2.9                 | <0.001  |
| PVR, Wood units            | 1.58 ± 0.75                   | 2.71 ± 1.25               | <0.001  |

Data are presented as means ± SD or numbers.

N = 100 except for FVC (n = 99), DLCO (n = 96), MMRC (n = 95), 6MWD (n = 91), Lowest SpO2 (n = 91).

doi:10.1371/journal.pone.0108339.t006

**Figure 3. Kaplan-Meier curves for survival according to MPAP (p = 0.005).** Survival curves were compared with log-rank statistics. doi:10.1371/journal.pone.0108339.g003
tive studies [31–32]. In addition, a previous study suggested that a minority of CTD-PH patients could also benefit from immunosuppressive therapies [33]. LD-CTD is a new term to describe a subgroup of patients who can benefit from specific therapies. However, it is unknown whether the therapeutic strategies and responses of immunosuppressive therapies are the same in LD-CTD as they are in CTD-ILD. In this study, thirty-nine patients were treated with corticosteroid and an immunosuppressive agent. Further trials of therapy are needed for LD-CTD, and may lead to characterization of the subgroup of patients who can benefit from specific therapies.

Our study has several limitations. First, this is a retrospective observational study. Collection of additional prospective data is warranted to confirm our findings. Second, LD-CTD was diagnosed on the basis of the proposed criteria without relying on the suggested histopathological features of CTD [11]. However, the central aim of this study was to investigate the prognostic ability of MPAP and other variables in patients with LD-CTD, and the clinical and physiologic evidence. Since not all patients underwent surgical lung biopsy, exclusion of these patients from the study would introduce significant selection bias. Therefore, we included all patients with LD-CTD who were diagnosed on the basis of serological criteria. Finally, our results are subject to treatment bias. Indications for therapy and choice of drug after the initial evaluation were not uniform among patients, limiting the evaluation of the prognosis.

In conclusion, we demonstrated that %FVC and MPAP have a statistically significant impact on survival in LD-CTD patients. MPAP evaluation provides additional information of disease status and will help physicians to predict mortality in LD-CTD.

Author Contributions
Conceived and designed the experiments: AS HT NW YK. Performed the experiments: AS HT NW YK. Analyzed the data: AS HT NW YK. Contributed to the writing of the manuscript: AS HT NW YK TK KK TM TY KS ON YH.

References
1. Behr J, Ryu JH (2006) Pulmonary hypertension in interstitial lung disease. Eur Respir J 31: 1357–1367.
2. Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, et al. (2013) Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 85: 456–463.
3. Mijia M, Carrillo G, Rojo-Serrano J, Estrada A, Suarez T, et al. (2009) Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 136: 10–15.
4. Patell NM, Ledetter DJ, Borucznak AC, Kasut SM (2007) Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 132: 990-1006.
5. Cottin V, Le Pavée J, Prevost G, Mal H, Humbert M, et al. (2010) Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 35: 105–111.
6. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, et al. (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138: 1383–1394.
7. Fischer A, du Bois R (2012) Interstitial lung disease in connective tissue disorders. Lancet 380: 609-698.
8. Corte TJ, Copley SJ, Desai SR, Zappala CJ, Hansell DM, et al. (2012) Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 39: 661–668.
9. Traid S, Armeris Z, Beigelman C, Haroce J, Costedoat N, et al. (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54: 184–191.
10. Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG (2013) CT of the lung in patients with connective tissue disease-associated interstitial lung disease: a call for clarification. Radiology 267: 110–121.
11. Fischer A, du Bois R (2012) Interstitial lung disease in connective tissue disorders. Lancet 380: 609-698.
12. Fischer A, West SG, Scigius JJ, Brown KK, du Bois RM (2010) Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 138: 251–256.
13. Alhamad EH, Al-Kassimi FA, AlBoukai AA, Raddaua E, Al-Hajjaj MS, et al. (2012) Comparison of three groups of patients with usual interstitial pneumonia. Respir Med 106: 1575–1585.
14. Arment FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271–1277.
16. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344–347.
17. Vitali C, Bombardieri S, Moutsopoulos HM, Balistreri G, Benvenuti W, et al. (1990) Preliminary criteria for the classification of Sjogren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36: 340–347.
18. Smolen JS, Steiner G (1989) Mixed connective tissue disease: to be or not to be? Arthritis Rheum 41: 768–777.
19. Eswar RL, Sontheimer RD (1991) Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 24: 959–966.
20. (1992) Standardization of Spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 152: 1107–1136.
21. (2004) Guideline of respiratory function tests-spirometry, flow-volume curve, diffusion capacity of the lung. Nihon Koki Gakkai Zasshi suppl. 1: 56.
22. (2002) ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111–117.
23. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, et al. (2003) Prognostic value of desaturation during a 6-minute walk test in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 168: 1084–1090.
24. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, et al. (2010) A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis.Eur Respir J 36: 1067–1072.
25. Nathan SD, Slabon OA, Barnett SD, Saggar R, Belzerio JA, et al. (2000) Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respirology 5: 469–477.
26. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, et al. (2003) Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167: 735–740.
27. Fischer A, Scigius JJ, Greshong SD, Cool CII, Sahin H, et al. (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134: 601–605.
28. Mathai SC, Hassoun PM (2012) Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 8: 413–425.
29. Dweik RA, Rounds S, Erzurum SC, Archer S, Fagan K, et al. (2014) An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med 189: 345–355.
30. Farkas L, Gaudie J, Voelkel NF, Kolb M (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 46: 1–15.
31. Vij R, Strek ME (2013) Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 143: 814–824.
32. Watanabe N, Sakamoto K, Taniguchi H, Kondoh Y, Kimura K, et al. (2014) Efficacy of combined therapy with cyclosporine and low-dose prednisolone in interstitial pneumonia associated with connective tissue disease. Respiration 87: 469–477.
33. Sanchez O, Sibon O, Jais X, Simonneau G, Humbert M (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130: 182–189.